SCHEMBL504043

SCHEMBL504043

COC1CCCC(C(=O)O)C1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.45
DPP4 P27487 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
ANPEP P15144 1/20 0.38
TSHR P16473 3/20 0.36
SLC6A1 P30531 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
SLC6A11 P48066 1/20 0.36
LMNA P02545 1/20 0.36
SLC6A13 Q9NSD5 1/20 0.36
EPHX2 P34913 1/20 0.36
HSD11B1 P28845 1/20 0.34
GABRR1 P24046 1/20 0.34
ACE P12821 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14425477 1.00 BTK (0.45) BTKDPP4DPP7PDE4APDE4B
SCHEMBL14041804 1.00 BTK (0.45) BTKDPP4DPP7PDE4APDE4B
SCHEMBL14042369 1.00 BTK (0.45) BTKDPP4DPP7PDE4APDE4B
SCHEMBL12065403 0.87 ACE (0.39) BTKDPP4DPP7PDE4APDE4B
SCHEMBL1072140 0.87 ACE (0.39) BTKDPP4DPP7PDE4APDE4B
SCHEMBL25527233 0.87 ACE (0.39) BTKDPP4DPP7PDE4APDE4B
SCHEMBL28001303 0.85 DPP4 (0.42) BTKDPP4DPP7TSHRSMN1; SMN2
SCHEMBL13235876 0.83 DPP4 (0.41) BTKDPP4DPP7TSHRSMN1; SMN2
SCHEMBL19346832 0.83 CES2 (0.41) BTKDPP4DPP7PDE4APDE4B
SCHEMBL17802928 0.83 PDE4A (0.40) BTKDPP4DPP7PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 WO claimed
WO-2025126110-A1 ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES iTeos Belgium SA (BE) 2025-06-19 WO claimed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 WO claimed
CN-119194329-A Cable staple bolt convenient to it is fixed 任丘市凯华通讯电力器材有限公司 2024-12-27 CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-116535365-A Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-08-04 CN claimed
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 US claimed
US-11053457-B2 Cleaning composition for semiconductor substrate JSR CORPORATION (JP) 2021-07-06 US claimed
EP-2903979-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES INHIBIKASE THERAPEUTICS INC (US) 2020-08-19 EP claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-20050272132-A1 Production of polyketides and other natural products BIOTICA TECHNOLOGY LIMITED (GB) 2005-12-08 US claimed
EP-1589031-A2 Production of polyketides and other natural products Biotica Technology Limited (GB) 2005-10-26 EP claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same PIERRE FABRE MEDICAMENT (FR) 2004-05-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD1, SLC29A1, ENTPD5 BTK 4423/4885DPP4 699/4885DPP7 569/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 BTK 2928/4885DPP4 2211/4885DPP7 2947/4885
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same CBR3, CBR1, HCCS BTK 4188/4885DPP4 3440/4885DPP7 1630/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 BTK 4510/4885DPP4 1780/4885DPP7 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.